

Citation: Xiong B, Li D, Wang J, Gyawali L, Jing J, Su L (2015) The Effect of Catheter Ablation on Left Atrial Size and Function for Patients with Atrial Fibrillation: An Updated Meta-Analysis. PLoS ONE 10 (7): e0129274. doi:10.1371/journal.pone.0129274

Editor: Alena Talkachova, University of Minnesota, UNITED STATES

Received: November 16, 2014

Accepted: May 6, 2015

Published: July 6, 2015

Copyright: © 2015 Xiong et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors have no support or funding to report. Li Su, Male, MD, Doctor of Department of Cardiology, The Second Affiliate Hospital of Chongqing Medical University, was without any source of funds. Bin Xiong, Male, a graduate student study at graduate college, Chongqing Medical University, was without any source of money. Dan Li, Female, a graduate student study at graduate college, Chongqing Medical University, was without any source of money. Jianling Wang, Male, a graduate student study at graduate college, **RESEARCH ARTICLE**

The Effect of Catheter Ablation on Left Atrial Size and Function for Patients with Atrial Fibrillation: An Updated Meta-Analysis

Bin Xiong, Dan Li, Jianling Wang, Laxman Gyawali, Jinjin Jing, Li Su*

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, The Chongqing Cardiac Arrhythmias Service Center, Chongqing, China

* sulicq@163.com

Abstract

Background

Catheter ablation (CA) for atrial fibrillation (AF) is now an important therapeutic modality for patients with AF. However, data regarding changes in left atrial (LA) function after CA have indicated conflicting results depending on the AF types, follow-up period, and the analytical imaging tools. The objective of this review was to analyze the effect of CA on the LA size and function for patients with AF.

Methods

We searched for studies regarding LA size and function pre- and post-ablation in PubMed, Embase, the Cochrane Library, and Web of Knowledge through May 2014. LA function was measured by LA ejective fraction (LAEF), LA active ejective fraction (LAAEF), or both. Total and subgroup analyses were implemented using Cochrane Review Manager Version 5.2. Weighted mean differences with 95% confidence intervals were used to express the results of continuous outcomes using fixed or random effect models. I² was used to calculate heterogeneity. To assess publication bias, Egger's test and Begg's funnel plot were performed using Stata 12.0.

Results

Twenty-five studies (2040 enrolled patients) were selected for this meta-analysis. The LA diameter (LAD), maximum LA volume, and minimal LA volume were significantly decreased post-ablation, as compared with those at a pre-ablation visit. Compared with the pre-ablation outcomes, we found no significant differences in LAEF/LAAEF at a post-ablation follow-up. Decreases in LA volume and LAEF remained significant post-ablation for paroxysmal AF (PAF); however, the LAEF was insignificant changes in persistent AF (PeAF). Heterogeneity was significant in spite which individual study was excluded. A publication bias was not found. In a meta-regression analysis, we did not find any factor that contributed to the heterogeneity.



Chongqing Medical University, was without any source of money. Laxman Gyawali, Male, a graduate student study at graduate college, Chongqing Medical University, was without any source of money. Jinjin Jing, Female, a graduate student study at graduate college, Chongqing Medical University, was without any source of money.

Competing Interests: The authors have declared that no competing interests exist.

Conclusion

With CA, LA volumes and LAD were decreased significantly in patients with AF; LAEF was not significant changes in patients with PeAF but decreased in those with PAF.

Introduction

Atrial fibrillation (AF) is the most commonly sustained tachyarrhythmia in clinical practice. It is associated with an increase in disease-related hospitalizations; a reduction in quality of life; complications such as congestive heart failure (HF), thromboembolism, and stroke; and an increased mortality risk [1-4]. Catheter ablation (CA) is considered an efficient mainstream therapy and potentially curative treatment for drug-refractory symptomatic AF [5, 6]. After successful ablation, patients with AF would experience improved left atrial (LA) function because of a reduction in AF burden. Nevertheless, it is noted that extensive atrial scar tissue formation produced by CA may result in adverse reactions in atrial function in AF patients. Although Jeevanantham et al. [7] reported successful CA for AF patients does not appear to adversely impact LA function, recent studies that investigated the impact of CA on LA function reported inconsistent results. Therefore, the purpose of this study was to update evidence regarding the effect of CA on the LA size and function in patients with AF.

Methods

Search Strategy

We performed a search for articles pertaining to CA in AF patients using the key words "atrial fibrillation," "catheter ablation," "atrial size," "left atrial function," and "left atrium function." We searched for all relevant studies, without any language limitations, in PubMed, Embase, the Cochrane Library, and Web of Knowledge through May 2014. Manual searches were also performed of the bibliographies.

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) randomized control trials (RCTs) or nonrandomized control trials were included; (2) follow-up imaging was performed no less than 3 months post-ablation; (3) primary outcome measurements changed regarding maximum LA volume (LAV-max), minimum LA volume (LAVmin), LA diameter (LAD), LA ejection fraction (LAEF; LAEF = [LAVmax – LAVmin]/LAVmax), LA active emptying fraction (LAAEF; LAAEF = {LA mid-diastolic volume just before atrial contraction [LAVmid]–LAVmin}/LAVmid), A wave velocity (A; *defined as the peak velocities of late transmitral flow measured by pulsed-wave Doppler echocardiography [DE]*), and the A' wave velocity (A'; *defined as the velocities of the mitral annulus during atrial contraction as measured by pulsed-wave tissue Doppler echocardiography [TDE]*) [<u>8</u>].

Exclusion criteria were as follows: (1) surgical ablation; (2) left ventricular ejection fraction (LVEF) of <50% or included HF patients in each enrolled study; (3) significant valvular disease including a stenotic valvular lesion or moderate-to-heavy regurgitation after valvular replacement; (4) heart dysfunction was caused by structural heart disease or another disease; (5) the LA parameters, as detailed previously, were not reported either pre- or post-ablation; and (6) median and inter-quartile range outcomes were reported.

Data Extraction and Quality Evaluation

Two reviewers (Xiong and Li) assessed the quality of each study and then independently extracted data from the included studies; another author (Wang) checked the data. The extracted information were: (1) basic information regarding those studies, including country and publication year; (2) the number of patients in the study; (3) patient characteristics; (4) type of catheter ablation performed for the treatment group; and (5) outcome measures, as previously defined. Any disagreement was resolved by discussion with a third party (Wang).

To evaluate the quality of the included studies, the following aspects had been performed, including (1) research design; (2) the representativeness of the enrolled patients; (3) the bias of loss to follow-up; and (4) other biases and limitations.

Statistical Analysis

Cochrane Review Manager Version 5.2 and Stata 12.0 were used to perform the statistical analysis. Weighted mean differences (WMDs) with 95% confidence intervals (CIs) were used for expressing continuous outcomes. Statistical heterogeneity was tested using the χ^2 test and was quantified using the I² statistic; significant heterogeneity was defined as a *P* of <0.10 or an I² of >50%. Data were pooled using a fixed effect or random effect model, based on whether the absence of significant heterogeneity existed. If the absence of heterogeneity was significant, the fixed effect model was performed, but if not, the random effect model was performed. Publication bias was evaluated using Egger's test and Begg's funnel plot with Stata 12.0; statistical significance was defined as a *P* of <0.05.

Results

Study Characteristics

We identified 1566 references from electronic databases using the previously described strategy. According to the inclusion criteria, 92 citations were retrieved and required further evaluation after screening the title, abstract, or both. Forty-one reviews and 14 case reports were excluded. Two studies reported median and inter-quartile range outcomes; 6 studies included surgical ablation; 2 studies had a follow-up of <3 months; and 2 studies included HF patients. Finally, 25 studies (2040 enrolled patients) were selected for this meta-analysis [9–33]. The selection process is demonstrated in a flow chart (Fig 1). The characteristics of each included study are listed in Table 1. The primary results of each included study are shown in Table 2.

All patients had underwent CA, one study [15] had repeated ablation. The majority of studies performed radiofrequency catheter ablation (RFCA), only one study [10] implemented cryoablation. Twelve studies [10, 12, 13, 17, 21, 22, 25, 26, 29–31, 33] had reported changes in LAD, LA volumes, or function on the basis of AF recurrence (AF recurrence defined as documented by body surface 12-lead electrocardiogram (ECG) or 24-hour Holter ECG lasting 30 seconds, despite being symptomatic or not, at any time from 3 months after CA [34]). Liu et al. [30] had compared two different treatment strategies [circumferential pulmonary vein ablation (CPVA) vs. segmental pulmonary vein isolation (SPVI)] on left atrial size in patients with lone paroxysmal AF (PAF). Nineteen studies [11, 12, 14–16, 18–24, 26–29, 31–33] had included patients with paroxysmal or non-paroxysmal AF, five studies [9, 10, 17, 25, 30] only included patients with PAF, one study [13] only included patients with persistent AF (PeAF), six studies [21, 23, 24, 26, 29, 32] included patients with permanent AF (only 49 enrolled patients). There were some co-morbidities including hypertension (HTN), diabetes mellitus (DM), and coronary artery disease (CAD) et al. in the majority of enrolled patients.




Fig 1. Flow chart of the literature search and study selection processes.

PLOS ONE

Quantitative Data Synthesis

The LAD (WMD, -0.91 mm; 95%CI, from -1.75 mm to -0.06 mm, P = 0.04; Fig 2), LAVmax (WMD, -6.48 mL; 95%CI, from -8.60 mL to -4.35 mL, P < 0.00001; Fig 3), and LAVmin (WMD, -4.17 mL; 95%CI, from -6.21 mL to -2.13 mL, P < 0.0001; Fig 4) were significantly decreased post-ablation, as compared with those pre-ablation. Nevertheless, a subgroup analysis was performed that was based on AF type; there were significant decreases in LA volumes (including LAVmax and LAVmin) for the AF patients. The LAD result indicated insignificant changes for patients with either paroxysmal or persistent AF (Figs 2–4).

Study	Area (yrs)	Number of Patients	Age	Men	Paroxysmal AF Persistent AF Permanent AF	Follow- Up (mon)	Duration of AF	Comorbidities	Medications	Type of Ablation	Type of Imaging	LVEF (%)	Patients with Recurrence	Success Rate
Dagres [9]	Greece	289	56±9	214	289	12	68±58mon	HTN (43%);	NA	PVCA	ΠE	62±10	123	166/289
2009				(74%)	NA			DM (5%);						(57%)
					NA			CAD (5%)						
Erdei [10]	Hungary	36	57±9	26	36	12	6.7±7.3yrs	HTN (75%);	AAD	CCA	TTE	63±5	21	15/36
2012				(72%)	NA			IHD (11%);						(42%)
					NA			OB (28%)						
Hof [11]	Netherlands	206	57 ±10	165	114	16	7±6yrs	HTN (35%);	AAD	PVAI	CMR	AN	37	169/206
2013				(%08)	92			IHD (10%)	(Class I and III)					(82%)
					NA									
Jahnke [12]	Germany	41	57 ±10	28	25	12	NA	HTN (66%);	NA	PVI	CMR	58±5	10	31/41
2011				(%89)	16			DM (5%);						(%92)
					NA			CAD (20%);						
								HLP (59%)						
Machino-	Japan	123	6709	104	NA	18	5.2±4.3yrs	HTN (56%);	AAD	PVI	TTE	NA	45	78/123
Ohtsuka [13]				(85%)	123			DM (7%);						(63%)
2013					NA			CAD (6%)						
Masuda [14]	Japan	115	62 ±10	82	92	ი	44.6 ±51.9mon	HTN (50%);	AAD	PVCA	MDCT	67±7	32	83/115
2012				(71%)	23			DM (13%)						(72%)
					NA									
Montserrat	Spain	158	53 ±11	120	77	9	52±34mon	HTN (44%)	AAD	RFCA	TTE	59±9	82	76/158
[15] 2011				(76%)	77									(48%)
2		ŝ	ĩ	Ċ	AN 6	c		1111 (1007)				ç		4
Nori 16	America	58	54 ±11	8	16	m	4.1 ±3.4yrs*	HIN (48%);	AN	PVAI	CMH	63 ±11*	AN	AN
2009				(62%)	13		2.0 ±1.0yrs#	DM (17%);				60 ±10#		
					NA			CAD (38%);						
								HLP (55%)						
Rodrigues	Brazil	28	53 ±13	22	28	ω	6 yrs	HTN (39%)	Amiodarone;	PVCA	TTE	NA	÷	17/28
[17] 2009				(%62)	NA		(3mon- 20yrs)		Propafenone;					(61%)
					NA				β-blocker					
Teh [<u>18]</u>	Australia	1	59±8	80	7	10	5.6±4.8yrs	NA	NA	RFCA	TTE	60±7	NA	NA
2012				(%82)	4									
					NA									
Tops [19]	Netherlands	148	54±9	117	112	13	5.3±4.5yrs	HTN (42%);	AAD;	PVI	ΠE	57±7	49	99/148
111				1001	30									(C/0/)

		Study	Area (yrs)	Number of Patients	Age	Men	Paroxysmal AF Persistent AF Permanent AF	Follow- Up (mon)	Duration of AF	Comorbidities	Medications	Type of Ablation	Type of Imaging	LVEF (%)	Patients with Recurrence	Success Rate
Jame 61 64 24 NA NA NA NA TE NA TE NA 1 1 1 2	400 61 64 64 04 04 04 15 04 15 1 67% 33 9 9 9 9 9 9 9 9 1 67% 35 9 9 9 9 9 9 9 9 1 63 9 9 9 10 6593 90<						NA									
International state Internatistate Internatistate <t< td=""><td>1 Tanua 1 0<td>Yoshida [20]</td><td>Japan</td><td>67</td><td>64±8</td><td>58</td><td>34</td><td>9</td><td>NA</td><td>NA</td><td>NA</td><td>PVI</td><td>TTE</td><td>NA</td><td>÷</td><td>56/67</td></td></t<>	1 Tanua 1 0 <td>Yoshida [20]</td> <td>Japan</td> <td>67</td> <td>64±8</td> <td>58</td> <td>34</td> <td>9</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>PVI</td> <td>TTE</td> <td>NA</td> <td>÷</td> <td>56/67</td>	Yoshida [20]	Japan	67	64±8	58	34	9	NA	NA	NA	PVI	TTE	NA	÷	56/67
I Fano. 6 0.0 0.0 TTC 624% 0.0	I Fano. I <td>2013</td> <td></td> <td></td> <td></td> <td>(87%)</td> <td>33</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>(84%)</td>	2013				(87%)	33									(84%)
Index Fare Fare <t< td=""><td>Image Fame Fame Fame Fame PU TE Easing PU TE Easing PU TE Easing PU PU Easing PU PU<!--</td--><td></td><td></td><td>:</td><td></td><td>:</td><td>NA</td><td></td><td>:</td><td></td><td></td><td>:</td><td></td><td></td><td></td><td></td></td></t<>	Image Fame Fame Fame Fame PU TE Easing PU TE Easing PU TE Easing PU PU Easing PU PU </td <td></td> <td></td> <td>:</td> <td></td> <td>:</td> <td>NA</td> <td></td> <td>:</td> <td></td> <td></td> <td>:</td> <td></td> <td></td> <td></td> <td></td>			:		:	NA		:			:				
	1 1	Reant [24]		48	53 ±9*	40	37	=	6±5yrs*	NA	β-blocker (29%);	PVI	Ш	62±5*	13	35/48
114 114 <td>143 143<td>2005</td><td></td><td></td><td>55 ±11&</td><td>(83%)</td><td>NA</td><td></td><td>12±9yrs&</td><td></td><td>Amiodarone (2%);</td><td></td><td></td><td>53±8&</td><td></td><td>(73%)</td></td>	143 143 <td>2005</td> <td></td> <td></td> <td>55 ±11&</td> <td>(83%)</td> <td>NA</td> <td></td> <td>12±9yrs&</td> <td></td> <td>Amiodarone (2%);</td> <td></td> <td></td> <td>53±8&</td> <td></td> <td>(73%)</td>	2005			55 ±11&	(83%)	NA		12±9yrs&		Amiodarone (2%);			53±8&		(73%)
3 pair 34 33 24 35 24 35 34 35 34 35 America 61 70% 6 7 <td>0 5µm 5H 2H 2H 2H 2H 2H 1H 1H<</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>11&</td> <td></td> <td></td> <td></td> <td>Flecainide (14%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	0 5µm 5H 2H 2H 2H 2H 2H 1H 1H<						11&				Flecainide (14%)					
America Cr050 6 America 67 24 26 58.5 Jvs HTN (31%) AD TG 5043 NA America 67 540 7% 6 58.5 Jvs HTN (31%) AD TG 5043 NA America 67 7% 7% 58.5 Jvs HTN (31%) AD TG 56.4 NA America 7% 24 24 Me% AD CP 7%	Montoa FG Totob E Statistic Multicity	Delgado	Spain	34	53 ±13	24	23	9	90±72mon	HTN (24%)	AAD	CPVA	3D-TTE	AN	13	21/34
	America 67 6 9 9 10 11 6 64 8 8 10 </td <td>29] 2008</td> <td></td> <td></td> <td></td> <td>(%02)</td> <td>9</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>(62%)</td>	29] 2008				(%02)	9									(62%)
America 67 56 40 6 58.5.1ys HIV (3%); AD PVA Tf., 50:13 IA America 8 2 N N DM(9%); C	America 67 56 49 40 64 5445.1ys HIN (3%) AD PVA TT 5013 IA America 58 27 73% 27 73% 27 73% 27 73% 27 73% 27 73% 27 73% 27 73% 27 73% 27 73% 24 240 240 240 240 240 240 24 27 24<						S									
		Verma [27]	America	67	56 ±10	49	40	9	5.8±5.1yrs	HTN (31%);	AAD	PVAI	TTE,	50±13	NA	NA
Meetia 5 54-yix CoD (19%); WD (15%) N CD Ameria 5 5 54-yix VDD (15%) N N Ameria 6 5 7 5 54-yix CD (19%); N Ameria 6 5 54-yix CD (19%); N CP 54-5 N Ameria 6 5 54-yix CD (19%); N CP 54-5 N Ameria 6 4 4 10 N Ameria 10 N 10 N	Marcia 55 24/10 CAD (3%) Number (3%)	2006				(73%)	27			DM (9%);			СТ			
							NA			CAD (19%);						
	America 36 51 24 27 54 544/s CaD (9%) NA CaD CaD 66 7< 645 NA 31 Family									VHD (15%)						
Image: section of the sectin of the section of the section		Lemola [23]	America	36	55 ±11	24	27	5	5±4yrs	CAD (9%)	NA	LACA	CT	56±5	NA	NA
Image Image <th< td=""><td>3 5 36 41 12 84460x5 HIN (22%) AD CMA 6049 17 21 21 41 1 12 84460x5 HIN (22%) AD CMA 6049 17 22 31 1 80 14 84450x5 HIN (33%) AD CMA 6049 17 23 31 1 8 8 900 10 16 18 16 18 16 18 16 18 16</td><td>2005</td><td></td><td></td><td></td><td>(67%)</td><td>NA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	3 5 36 41 12 84460x5 HIN (22%) AD CMA 6049 17 21 21 41 1 12 84460x5 HIN (22%) AD CMA 6049 17 22 31 1 80 14 84450x5 HIN (33%) AD CMA 6049 17 23 31 1 8 8 900 10 16 18 16 18 16 18 16 18 16	2005				(67%)	NA									
3 3 3 5 5 4 4 1 12 8.443% HTN (22%) AD CPM 6049 17 1	3 3 3 5 5 4 1 12 8449/s HM (2%) AD CM GM G03 17 1 0% 1 0% 1 2 244.5% HM (2%) AD CM G03 17 2 0% 1 0% 1 2						9&									
	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Perea [33]	Spain	55	52 ±11	44	41	12	8.4±8yrs	HTN (22%);	AAD	CPVA	CMR	60±9	17	38/55
	Image: Normal indext and the state of t	2008				(%08)	14			SHD (16%)						(%69)
Image: Mathematic of a constraint of a	Modellation 51 5245 72 72 ACL and/or 74 1 74 1 (87%) 1 (87%) 1 (11,5%) (11			2		0	AN 20	c					1	4	2	10,01
(67%) 11 IND (7%) Diuteic (15%); 8 Amodarone 24%); Amodarone 8 Amodarone 24%); Amodarone 1 1 24%); Setalol (12%); Setalol (12%); 1 1 24%); Setalol (12%); Setalol (12%); 1 1 24%); Setalol (12%); Setalol (12%); 1 1 1 Setalol (12%); Setalol (12%); 1 1 1 1 Setalol (12%); Setalol (12%); 1 1 1 1 1 Setalol (12%); Setalol (12%); 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 <t< td=""><td>(67%) 11 IHD (7%) Duratic (15%); 8 8 Aniodarone (2%); Aniodarone (2%); 8 8 Aniodarone (2%); 24%); 1 1 24%); Sotalo (12%); 1 1 24%); Sotalo (12%); 1 1 24%); Bobole (2%); 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1<</td><td>Muller 32</td><td></td><td>91</td><td>59±8</td><td>6/</td><td>72</td><td>Q</td><td>6.4±5.8yrs</td><td>HTN (33%);</td><td>ACEI and/or ARB(30%);</td><td>IV4</td><td>Ξ</td><td>AN</td><td>21</td><td>70/91</td></t<>	(67%) 11 IHD (7%) Duratic (15%); 8 8 Aniodarone (2%); Aniodarone (2%); 8 8 Aniodarone (2%); 24%); 1 1 24%); Sotalo (12%); 1 1 24%); Sotalo (12%); 1 1 24%); Bobole (2%); 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1<	Muller 32		91	59±8	6/	72	Q	6.4±5.8yrs	HTN (33%);	ACEI and/or ARB(30%);	IV4	Ξ	AN	21	70/91
Reindactore Amodatore C4%): C4%): C4%): Sotalol (12%): C4%): Miltiki: C4%): Miltiki: C4%: Miltiki: Motore: Sotaloi: Motore: Sotaloi: MA Miltiki: MA Miltiki: Mateore: CAD (5%): Mateore: Sotaloi: Mateore: Sotaloi: MA Miltiki: MA Miltiki: MA Miltiki: MA Miltiki: MA Miltiki: MA Mil	Amodatone Amodatone R1 R1 R1 R1 R1 R1 R1 R1 R1 R1 R1 R1 R1 R1	2008				(87%)	11			IHD (7%)	Diuretic (15%);					(%22)
Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%); Belocker 9.90cker 9.90cker <t< td=""><td>Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%) Amodarons FFCA 57±9 19 Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%) Amodarons FFCA 57±9 19 Netherlands 57 56±9 14 A3 Amodarons FFCA 30-TTE 57±9 19 No 14 N N N MO40No FFCA 30-TTE 57±9 19 N 14 N Amodarons FFCA S0 19 19 19 19 N 14 N CD (5%) FFCA 30-TTE 57±9 19 19 N N N N CD (5%) FFCA 30-TTE 19 19 N N N N N S0±0 19 19 19 N N N N N S0±0 19 19 19 19 19 N N N N</td><td></td><td></td><td></td><td></td><td></td><td>8</td><td></td><td></td><td></td><td>Amiodarone (24%);</td><td></td><td></td><td></td><td></td><td></td></t<>	Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%) Amodarons FFCA 57±9 19 Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%) Amodarons FFCA 57±9 19 Netherlands 57 56±9 14 A3 Amodarons FFCA 30-TTE 57±9 19 No 14 N N N MO40No FFCA 30-TTE 57±9 19 N 14 N Amodarons FFCA S0 19 19 19 19 N 14 N CD (5%) FFCA 30-TTE 57±9 19 19 N N N N CD (5%) FFCA 30-TTE 19 19 N N N N N S0±0 19 19 19 N N N N N S0±0 19 19 19 19 19 N N N N						8				Amiodarone (24%);					
Netherlands 57 56±9 44 43 8-blocker 8-blocker 8-blocker Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%) Amiodarone; RFCA 3D-TTE 57±9 19 Netherlands 57 56±9 44 43 8 4.6±4.1ys HTN (44%); Amiodarone; RFCA 3D-TTE 57±9 19 Notes 14 14 Amiodarone; RFCA 3D-TTE 57±9 19 19 Notes 14 14 Amiodarone; RFCA 3D-TTE 57±9 19 19 Notes 14 14 Notes RFCA 3D-TTE 57±9 19 19 Notes 14 Retender; Retender; Retender; Retender; 19 19 Notes 14 Retender; Retender; Retender; Retender; 19 19 19 Notes 14 Retender; Retender; Retender; Retender; Retender; 19 19 Notes <td>Including 57 6 (31%); 10 (31%); Netherlands 57 56±9 44 43 9 looker 10 <</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Sotalol (12%);</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Including 57 6 (31%); 10 (31%); Netherlands 57 56±9 44 43 9 looker 10 <										Sotalol (12%);					
Netherlands 57 56±9 44 43 8 4.6±4.1yrs HTN (44%) Amiodarone; FFCA 3D-TTE 57±9 19 Netherlands 57 56±9 44 43 8 4.6±4.1yrs HTN (44%); Amiodarone; FFCA 3D-TTE 57±9 19 N 1 Propatenone;	Netherlands 57 8-blocker 8-b										lc (31%);					
Netherlands 57 56±9 44 43 8 4.6±4.1yrs HTN (44%); Amiodarone; RFCA 3D-TTE 57±9 19 77%1 14 DM (11%); Propatenone; RFCA 3D-TTE 57±9 19 71%1 14 DM (11%); Propatenone; RFCA 3D-TTE 57±9 19 71%1 14 DM (11%); Propatenone; RFCA 3D-TTE 57±9 19 71<1	Netherlands 57 64 43 8 4.6±4.1yrs HTN (44%); Amiodarone; RFC4 3D-TTE 57±9 19 7 77% 14 D Propatone; Propatone; Propatone; 57±9 19 7 7% 14 D DN (11%); Propatone;										β-blocker (43%)					
(77%) 14 DM (11%); Propatenone; NA CAD (5%) Flecainide; Status Sotalo; ACEI and/or ARBs(46%)	(77%) 14 DM (11%); Propatenore; NA CAD (5%) Flecainide; Scalol; Scalol; A ACEI and/or	Marsan [31]	Netherlands		56±9	44	43	ω	4.6±4.1yrs	HTN (44%);	Amiodarone;	RFCA	3D-TTE	57±9	19	38/57
NA CAD (5%)	NA CAD (5%) Flecainide; Sotalol; ACEI and/or ARBs(46%)	2008				(%27)	14			DM (11%);	Propafenone;					(67%)
Sotalol; ACEI and/or ARBs(46%)							NA			CAD (5%)	Flecainide;					
ACEI and/or ARBs(46%)											Sotalol;					
											ACEI and/or ARBs(46%)					

Table 1.	Table 1. (Continued)													
Study	Area (yrs)	Number of Patients	Age	Men	Paroxysmal AF Persistent AF Permanent AF	Follow- Up (mon)	Duration of AF	Comorbidities	Medications	Type of Ablation	Type of Imaging	LVEF (%)	Patients with Recurrence	Success Rate
Beukema	Netherlands	105	53 ±10	88	52	15	6±5.1yrs*	HTN (26%);	AAD	PVI	Ш	54±4	34	71/105
[22] 2005				(84%)	53		7.6±6yrs#	DM (5%)						(68%)
					NA									
Choi [28]	Korea	ŝ	56 ±10	27	21	ო	63±47mon	HTN (21%);	ACEI or ARB (24%);	RFCA	TTE	53±6	NA	NA
2008				(82%)	12			DM (6%);	CCB (30%);					
					NA			CAD (6%)	β-blocker (15%);					
									Amiodarone (30%);					
									Propafenone (30%);					
									Flecainide (6%)					
Liu [<u>30</u>]	China	120	6709	80	120	12	2.6±1.4yrs	NA	Amiodarone;	CPVA	TTE	67±3	42	78/120
2008				(83%)	NA				Losartan	SPVI				(65%)
					NA									
Tops [26]	Netherlands	57	53±8	45	35	e	6±5yrs	HTN (30%);	AAD	RFCA	TTE	55±7	18	39/57
2006				(%62)	18			CAD (7%);						(%89)
					4			VHD (11%)						
Lemola [21]	America	41	54 ±12	33	25	4	5±3yrs	HTN (21%);	NA	LACA	ст	55±8	8	33/41
2004				(%08)	NA			SHD (41%)						(%0%)
					16									
Tsao [25]	China	45	60 ±13	36	45	21	NA	NA	AAD	PVI	CMR	NA	10	35/45
2005	Taiwan			(%08)	NA									(22%)
					NA									
* Paroxys	* Paroxysmal Atrial Fibrillation	illation 												
# Persiste & Chronic	 # Persistent Atrial Fibrillation & Chronic Atrial Fibrillation 	ation												
	NA = Not Available: mon ≡ months: vrs = vears) = months:	VIS = VE	ars										
HTN = Hy	HTN = Hypertension; DM = Diabetes Mellitus; CAD =	M = Diabete	s Mellitu	is; CAD		/ Disease;	OB = Obesit	Coronary Artery Disease; OB = Obesity; IHD = Ischemic Heart Disease; HLP = Hyperlipidemia; VHD = Valvular Heart	nic Heart Disea	se; HLP = H	Hyperlipider	nia; VHD	= Valvular He	art
Disease; {	Disease; SHD = Structural heart disease.	ral heart dis	ease.											
ACEI = Ai	ngiotensin Cor	iverting Enz	yme Inł	ibitors; /	ACEI = Angiotensin Converting Enzyme Inhibitors; ARB = Angiotensin Receptor Blocker; CCB = Calcium-channel Blocker; AAD = Anti-Arrhythmic Drugs.	n Recepto	r Blocker; C(CB = Calcium-cl	hannel Blocker;	AAD = Anti	i-Arrhythmid	c Drugs.		
	Radiofrequency	/ Catheter /	vblation;	CCA = (RFCA = Radiofrequency Catheter Ablation; CCA = Cryoballoon Catheter Ablation; PVI = Pulmonary vein isolation; PVA = Pulmonary Vein Antrum Isolation; CPVA/	eter Ablati	on; PVI = Pu	Ilmonary vein ist	olation; PVAI =	Pulmonary	Vein Antrur	n Isolatio	n; CPVA/	
	urcumerenual				PVOA = Olicumereniai Purnorary Ven Garreter Abranon, SPVI = Segmeniai Purnorary Ven Isolauon, LAOA = Hauloirequency Len Aniai Olicumereniai Abranom OMP - Contro Momentic Processio Incontro Tarra Transferratio Fabroratio conchication Information MOCT - Mutator	egmental - choocudio	Puimonary v		ACA = Hadioire	quency Leil		JITHERERUS	al Ablauon. Computed To	
	arulac Magnet	IC Resoliari	e Imag	⊔ 0; - i ⊑			ograpriy; i Ec		ageal Echocarc	iograpriy; iv			Computed to	mograpny.
Atrial fibrii	llation recurrer	ice is define	d as do	cumente	Atrial fibrillation recurrence is defined as documented by body surface 12-lead electrocardiogram (ECG) or 24-hour Holter ECG lasting 30 seconds, despite being symptomatic or	e 12-lead €	ectrocardio	gram (ECG) or :	24-hour Holter	ECG lasting	30 second	s, despite	eing sympto	matic or

not, at any time from 3 months after catheter ablation.

doi: 10.1371/journal.pone.0129274.t001

Study	LAD	LAD	LAVmax	LAVmax	LAVmin	LAVmin	LAEF	LAEF	LAAEF	LAAEF	A Wave	A Wave	A' Wave	A' Wave
	Pre-ablation	Post-ablation	Pre-ablation	Post-ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre-ablation	Post-ablation
Dagres [9]	42±6*	41±5*	NA	NA	NA	NA	NA	NA	NA	NA	59±23*	53±12*	NA	NA
2009														
Erdei [10]	54±6(NR) *	56±5(NR) *	67±20(NR) *	69±15(NR) *	30±12(NR) *	32±11(NR) *	55±8(NR) *	55±9(NR) *	NA	NA	NA	NA	10.7±2.7(NR) *	10.8±3.1(NR) *
2012	55±5(R) *	59±6(R) *	73±23(R) *	81±24(R) *	38±19(R) *	44±20(R) *	48±11(R) *	47±11(R) *					9.8±2.1(R) *	10.2±2.7(R) *
Hof [11]	NA	NA	116.6±27.7*	104.1±25.3*	62.8±20*	57.9±18.9*	43.8±9.3	41.2±9.6	27.9±9.5	25.4±9.5	NA	NA	NA	NA
2013			135.6±35.9#	121.5±34.8#	80.2±32.1#	73.8±27.1#								
Jahnke	AN	NA	98±18(NR)	83.7±19.3(NR)	68.2±23.7 (NR)	50.4±18.4 (NR)	31.4±17.3 (NR)	40.7±13.2 (NR)	AN	NA	NA	NA	AA	NA
[12] 2011			116.7±20.3(R)	108±19.8(R)	80.2±24.9 (R)	71.3±23.8 (R)	31.8±15.2 (R)	34.9±13.9 (R)						
Machino-	NA	NA	48±25(NR) #	34±16(NR) #	40±19(NR) #	23±12(NR) #	24±17(NR) #	36±14 NR) #	NA	NA	54±12#	63±19#	NA	NA
			57±23(R) #	59±22(R) #	47±16(R) #	49±20(R) #	21±16(R) #	17±14(R) #						
[13] 2013														
	NA	NA	57.3±17.7*	53.2±14.9*	NA	NA	47.4±11.8*	44.9±10.6*	NA	NA	NA	NA	NA	NA
[14] 2012			65.8±28.4#	53.4±22.8#			32.7±11.4#	39.1±11.5#						
Montserrat	42±6*	41±6*	53±16*	47±15*	30±12*	28±11*	44±16*	40±13*	37±23*	44±25*	NA	NA	NA	NA
[15] 2011	44±6#	43±5#	64±20#	56±18#	46±18#	39±16#	28±16#	31±17#						
Nori [16]	AN	AN	37±6.4*	28.5±5.9*	19.7±5.7*	16.3±5.9*	47.3±10.1*	42.7±9.4*	33.4±8.3*	26.2 ±7.9*	NA	NA	AN	NA
2009			41.4±8.7#	36.7±10#	31.7±9.3#	24±8.8#	24.1±11.8#	34.8±10.2#						
Rodrigues	41±7*	40 1 6*	56±21 (NR)*	58±20(NR)*	30±15*	34±15*	47±8*	43±8*	NA	NA	55±15*	58±19*	7.9±2.3*	8.1±2.8*
[17] 2009			53±14(R)*	57±20(R)*										
Teh [18]	45±7	42±6	76±30	63±23	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
_	43±4	40±4	31±7	21±6	19±6	12±5	41±14	46±11	NA	NA	NA	NA	NA	NA
	38±7*	40±8*	NA	NA	NA	NA	NA	NA	NA	AA	AA	AA	NA	AA
	41±6#	40±8#												
Ð	59.7±7.3*	53.19±7.7*	NA	NA	NA	NA	NA	NA	30.9±13.5*	34±11.3*	NA	AN	NA	NA
	68.4±8.1&	60.68±6.5&							5.4±3.6&	21.8±11&				
Delgado	40±6(NR)	39±6(NR)	50±11(NR)	45±10(NR)	26±13(NR)	24±8(NR)	49±19(NR)	48±18(NR)	25±21(NR)	26±21 (NR)	31±27 (NR)	30±26 (NR)	NA	NA
[29] 2008	42±7(R)	43±9(R)	64±19(R)	53±22(R)	32±12(R)	30±15(R)	49±14(R)	43±13(R)	23±19(R)	18±12(R)	22±36(R)	42±16(R)		
Ы	45.9±10.2	44.4±4.5	94.5±28.1	85.8±18.2	78.6±23.8	66.8±13.9	16.7±5.8	22.1±5.4	NA	NA	42.8±20.9	61.9±17.3	NA	NA
	NA	NA	121±40*	95±30*	87±39*	78±27*	32±13*	21±8*	AA	AA	AA	NA	NA	AA
Perea [33]	NA	AN	98±19.9(NR)	84.9±17.1(NR)	58.6±16.1 (NR)	52.2±12.1 (NR)	40.2±11.5 (NR)	38.1±9.8 (NR)	AN	NA	NA	NA	NA	NA
2008			126.2±32.8(R)	103.5±28.1(R)	78.4±22.2 (R)	75.8±24.3 (R)	37.4±10.1 (R)	26.9±10.2 (R)						
Muller [32]	56±8	53±7	59.6±21.3	51±15.5	NA	NA	NA	NA	NA	NA	59.7±20.4	59±16.1	8.9±2.9	9.8±3.4
2008														
Marsan	NA	NA	26±8(NR)	23±7(NR)	13±5(NR)	10±4(NR)	52±10(NR)	58±10(NR)	22±8(NR)	33±9 (NR)	AN	AN	NA	NA
[31] 2008			31±8(R)	32±8(R)	16±7(R)	18±6(R)	47±13(R)	42±11(R)	24±7(R)	15±9(R)				
Baildama	* VOINT VIDA		014	212			VI V	VI V	VIV		VIV	VIV	212	VIV

Table 2. ((Table 2. (Continued)													
Study	LAD	LAD	LAVmax	LAVmax	LAVmin	LAVmin	LAEF	LAEF	LAAEF	LAAEF	A Wave	A Wave	A' Wave	A' Wave
	Pre-ablation	Post-ablation	Pre-ablation	Post-ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre- ablation	Post- ablation	Pre-ablation	Post-ablation
[22] 2005	44±5.8(NR) #	40±4.5(NR) #												
	45±6.5(R) #	49±5.4(R) #												
Choi [28]	41±5.4	39±6.4	63.4±20.7	50.7±16.6	43.8±18.2	35.1±12.9	31.8±12.8	30.9±10	NA	NA	60.7±22.7	44.8±16.7	9.7±1.9	7.6±1.6
2008														
Liu CPVA	33.8±3.6(NR) *	33.8±3.6(NR) * 32.2±2.5(NR) *	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
[30]	34.9±2.8(R) *	34.1±1.9(R) *												
2008 SPVI	34.8±2.8(NR) *	35±2.4(NR) *	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	35.4±2.7(R) *	38.4±2.8(R) *												
Tops [26]	45±3(NR)	42±3(NR)	59±12(NR)	50±11(NR)	37±9(NR)	31±7(NR)	NA	NA	NA	NA	NA	NA	NA	NA
2006	45±3(R)	48±3(R)	63±7(R)	68±8(R)	43±7(R)	47±7(R)								
Lemola	NA	NA	115±39(NR)	97±35(NR)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
[21] 2004			128±80(R)	135±70(R)										
Tsao [25]	33.5±5.9(NR) *	33.5±5.9(NR) * 32.5±6.9(NR) *	61.5±19.1(NR) *	56.6±17.1(NR) *	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
2005	34.1±6.6(R) *	36.2±6.4(R) *	61.1±17.5(R) *	78.7±25.3(R) *										
* Paroxvsr	* Paroxysmal Atrial Fibrillation	lation												
# Persister	# Persistent Atrial Fibrillation	tion												
& Chronic	& Chronic Atrial Fibrillation	u												
NR = Not F	Recurrence; R	= Recurrence	NR = Not Recurrence; R = Recurrence; NA = Not Avai	ailable										
LAD = left	atrial diameter	∵; LAVmax = π	LAD = left atrial diameter; LAVmax = maximum left atrial volume; LAVmin = minimum left atrial volume; LAEF = left atrial ejective fraction; LAAEf = left atrial active ejective fraction;	rial volume; LA	Vmin = min	imum left at	rial volume;	LAEF = lef	t atrial eject	ive fractio	n; LAAEf	= left atria	al active ejecti	/e fraction;

Other abbreviations and AF Recurrence defined as previously detailed.

A wave = A wave velocity; A' wave = A' wave velocity

doi:10.1371/joumal.pone.0129274.t002

	Post-	ablatio	on	Pre-	ablati	on		Mean Difference	Mean Difference
Study or Subaroup	Mean			Mean			Welaht	IV. Random, 95% C	
1.1.1 LAD Studies With Parox									
Beukema PAF Nonrecur 2005	37.5	3.5	39	40.5	4.4	39	4.6%	-3.00 [-4.76, -1.24]	
Dagres PAF 2009	41	5	289	42	6	289	5.5%	-1.00 [-1.90, -0.10]	-
Erdei PAF Nonrecur 2012	56	5	15	54	6	15	2.6%	2.00 [-1.95, 5.95]	
Erdei PAF Recur 2012	59	6	21	55	5	21	3.1%	4.00 [0.66, 7.34]	
Liu CPVA PAF Nonrecu 2008	32.2	2.5	28	33.8	6.1	28	3.9%	-1.60 [-4.04, 0.84]	
Liu CPVA PAF Recur 2008	34.1	1.9	32	34.9	2.8	32	5.2%	-0.80 [-1.97, 0.37]	-8-
Liu SPVI PAF Nonrecu 2008	35	2.4	46	34.8	2.8	46	5.3%	0.20 [-0.87, 1.27]	+
Liu SPVI PAF Recur 2008	38.4	2.8	14	35.4	2.7	14	4.4%	3.00 [0.96, 5.04]	
Montserrat PAF 2011	41	6	77	42	6	77	4.5%	-1.00 [-2.90, 0.90]	
Reant PAF 2005	53.19	7.7	37	59.7	7.3	37	3.0%	-6.51 [-9.93, -3.09]	
Tsao PAF Nonrecur 2005	32.5	6.9	35	33.5	5.9	35	3.4%	-1.00 [-4.01, 2.01]	
Tsao PAF Recur 2005	36.2	6.4	10	34.1	6.6	10	1.6%	2.10 [-3.60, 7.80]	
Yoshida PAF 2013	40	8	34	38	0.0	34	2.9%	2.00 [-1.57, 5.57]	+ -
Subtotal (95% CI)	-10	0	677	00	'	677	49.9%	-0.36 [-1.45, 0.74]	
Heterogeneity: Tau ² = 2.49; Chi	$^{2} = 46.30$	df = 11		00001)· ² =			0.00 [0, 0]	1
Test for overall effect: Z = 0.64 (-	ui - 12	- (1 - 1		,, ı –	7 - 70			
1.1.2 LAD Studies With Persis	tont AE								
Beukema PeAF Nonrecu 2005		4 -				~~	0.00/	4001054 410	
	40	4.5	32	44	5.8	32	3.8%	-4.00 [-6.54, -1.46]	
Beukema PeAF Recur 2005	49	5.4	21	45	6.5	21	2.8%	4.00 [0.39, 7.61]	
Montserrat PeAF 2011	43	5	77	44	6	77	4.7%	-1.00 [-2.74, 0.74]	
Yoshida PeAF 2013	40	8	33 163	41	6	33 163	3.0%	-1.00 [-4.41, 2.41]	<u> </u>
Subtotal (95% CI)							14.3%	-0.71 [-3.50, 2.07]	
Heterogeneity: Tau ² = 5.97; Chi		df = 3	(P = 0.	005); 1*	= 769	6			
Test for overall effect: Z = 0.50 ((P = 0.61)								
1.1.3 LAD Studies With Poole	d Data								
Choi 2008	39	6.4	33	41	5.4	33	3.5%	-2.00 [-4.86, 0.86]	
Delgado Nonrecur 2008	39	6	21	40	6	21	2.8%	-1.00 [-4.63, 2.63]	
Delgado Recur 2008	43	9	13	42	7	13	1.4%	1.00 [-5.20, 7.20]	
Muller 2008	53	7	91	56	8	91	4.2%	-3.00 [-5.18, -0.82]	
Reant Chronic 2005	60.68	6.5	11	68.4	8.1	11	1.4%	-7.72 [-13.86, -1.58]	
Rodrigues 2009	40	6	28	41	7	28	3.0%	-1.00 [-4.41, 2.41]	
Teh.AW 2012	42	6	11	45	7	11	1.7%	-3.00 [-8.45, 2.45]	
Tops 2011	40	4	93	43	4	93	5.3%	-3.00 [-4.15, -1.85]	+
Tops Nonrecur 2006	42	3	39	45	3	39	5.1%	-3.00 [-4.33, -1.67]	
Tops Recur 2006	48	3	18	45	3	18	4.4%	3.00 [1.04, 4.96]	-
Verma 2006	44.4	4.5	41		10.2	41	3.0%	-1.50 [-4.91, 1.91]	
Subtotal (95% CI)			399			399	35.8%	-1.75 [-3.24, -0.25]	\bullet
Heterogeneity: Tau ² = 3.78; Chi	² = 35.92.	df = 10) (P < (0.0001)	; ² = 7	2%			
Test for overall effect: Z = 2.29 (,	•				
Total (95% CI)			1239			1239	100.0%	-0.91 [-1.75, -0.06]	•
Heterogeneity: Tau ² = 3.18; Chi	² = 107.73	. df = 3		0.0000)1): l² =				
Test for overall effect: Z = 2.10 (-		.,, .				-20 -10 0 10 20
Test for subaroup differences: C		df = 1	7 (P = () 34) I ²	= 7 79	%			Favours [Post-ablation] Favours [Pre-ablation
Fig 2 A forest plot of com									and a set able to a



PLOS ONE

Compared with the pre-ablation outcomes, we found no significant differences in LAEF (WMD, 0.07%; 95%CI, from -2.22% to 2.36%, P = 0.95; Fig 5) and LAAEF (WMD, -1.86%; 95%CI, from -3.92% to 7.63%, P = 0.48; Fig 6). Subsequently, we performed a subgroup analysis based on the AF type, and there were insignificant differences among those studies with either PAF or PeAF, except for LAEF with PAF (WMD, -3.80%; 95%CI, from -6.65% to -0.95%, P = 0.009; Fig 5). Finally, we analyzed the A wave velocity (A) and A' wave velocity (A'), and there were insignificant differences during follow-up imaging for CA treatment, as compared with pre-ablation (Figs 7 and 8).

Subsequently, we implemented a subgroup analysis on the basis of AF recurrence. There were significant decreased in LAD (WMD, -1.63 mm; 95%CI, from -3.01 mm to -0.24 mm, P = 0.02, <u>S1 Fig</u>), LAVmax (WMD, -7.53 mL; 95%CI, from -11.09 mL to -3.97 mL, P < 0.0001, <u>S2 Fig</u>), and LAVmin (WMD, -6.73 mL; 95%CI, from -11.07 mL to -2.39 mL, P = 0.002, <u>S3 Fig</u>) with no recurrence AF during post-ablation follow-up, but not those with AF recurrence,



	Post	-ablati	on	Pre-	ablati	on		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
2.1.1 LAVmax Studies Wit	h Parox	ysmal	AF				-		
Erdei PAF Nonrecur 2012	69	15	15	67	20	15	2.0%	2.00 [-10.65, 14.65]	_ _ _
Erdei PAF Recur 2012	81	24	21	73	23	21	1.7%	8.00 [-6.22, 22.22]	
Hof PAF 2013	104.1	25.3	114	116.6	27.7	114	3.8%	-12.50 [-19.39, -5.61]	
Lemola PAF 2005	95	30	27	121	40	27	1.1%	-26.00 [-44.86, -7.14]	
Masuda PAF 2012	53.2	14.9	92	57.3	17.7	92	4.9%	-4.10 [-8.83, 0.63]	
Montserrat PAF 2011	47	15	77	53	16	77	4.8%	-6.00 [-10.90, -1.10]	
Nori PAF 2009	28.5	5.9	16	37	6.4	16	5.1%	-8.50 [-12.77, -4.23]	
Rodrigues PAF NonRecur	58	20	17	56	21	17	1.7%	2.00 [-11.79, 15.79]	— —
Rodrigues PAF Recur	57	20	11	53	14	11	1.6%	4.00 [-10.43, 18.43]	
Tsao PAF Nonrecur 2005	56.6	17.1	35	61.5	19.1	35	3.2%	-4.90 [-13.39, 3.59]	+
Tsao PAF Recur 2005	78.7	25.3	10	61.1	17.5	10	1.0%	17.60 [-1.47, 36.67]	A
Subtotal (95% CI)			435			435	30.8%	-4.32 [-8.35, -0.29]	\blacksquare
Heterogeneity: Tau ² = 21.93	; Chi ² =	24.00,	df = 10	(P = 0.	008);	² = 58%	6		
Test for overall effect: Z = 2	.10 (P =	0.04)		-	-				
			_						
2.1.2 LAVmax Studies Wit						_]
Hof PeAF 2013	121.5	34.8	92		35.9	92	2.6%	-14.10 [-24.32, -3.88]	
Machino PeAF Nonrecur	34	16	62	48	25	62	3.6%	-14.00 [-21.39, -6.61]	
Machino PeAF Recur	59	22	45	57	23	45	2.9%	2.00 [-7.30, 11.30]	
Masuda PeAF 2012	53.4	22.8	23	65.8	28.4	23	1.5%	-12.40 [-27.28, 2.48]	
Montserrat PeAF 2011	56	18	77	64	20	77	4.2%	-8.00 [-14.01, -1.99]	
Nori PeAF 2009	36.7	10	13	41.4	8.7	13	3.7%	-4.70 [-11.91, 2.51]	
Subtotal (95% CI)			312			312	18.5%	-8.17 [-12.95, -3.39]	
Heterogeneity: Tau ² = 16.20			•	P = 0.09); ² = ·	47%			
Test for overall effect: Z = 3	.35 (P =	0.0008)						
2.1.3 LAVmax Studies Wit	h Poolo	d data							
Choi 2008	50.7		33	62.4	20.7	33	3.0%	-12.70 [-21.75, -3.65]	
Delgado Nonrecur 2008	45	10.0	21	50	20.7	21	4.1%	-5.00 [-11.36, 1.36]	_ _ _
Delgado Recur 2008	53	22	13	64	19	13	1.4%	-11.00 [-26.80, 4.80]	
Jahnke Nonrecur 2011	83.7		31	98	18	31	2.9%	-14.30 [-23.59, -5.01]	
Jahnke Recur 2011	108	19.3	10	116.7		10	1.2%	-8.70 [-26.28, 8.88]	
Lemola Nonrecur 2004	97	35	33	115	20.3	33	1.2%	-18.00 [-35.88, -0.12]	
Lemola Recur 2004	135	70	33	128	80	33		7.00 [-113.29, 127.29]	·
Marsan Nonrecur 2008	23	7	38	26	8	38	5.5%	-3.00 [-6.38, 0.38]	
Marsan Recur 2008	32	8	19	31	8	19	4.7%	1.00 [-4.09, 6.09]	
Muller 2008	51	15.5	91	59.6	21.3	91	4.5%	-8.60 [-14.01, -3.19]	
Perea Nonrecur 2008	84.9	17.1	38	98	19.9	38	3.2%	-13.10 [-21.44, -4.76]	
Perea Recur 2008	103.5		30 17		32.8	30 17	3.2% 0.9%	-13.10 [-21.44, -4.76] -22.70 [-43.23, -2.17]	
Teh.AW 2012	63	20.1	11	76	32.0	11	0.9%	-13.00 [-35.34, 9.34]	
Tops 2011	22	25	93	31	7	93	6.1%	-9.00 [-10.87, -7.13]	-
Tops Nonrecur 2006	50	11	39	59	12	39	4.7%	-9.00 [-14.11, -3.89]	
Tops Recur 2006	68	8	18	63	7	18	4.7%	5.00 [0.09, 9.91]	_ _
Verma 2006		18.2	26		28.1	26	4.8%	-8.70 [-21.57, 4.17]	— — — — — — —
Subtotal (95% CI)	00.0	10.2	534	04.0	20.1	534	50.7%	-7.21 [-10.35, -4.06]	\bullet
Heterogeneity: Tau ² = 21.74	l· Chi² =	53 69		(P < ∩	00001			The freed, wool	•
Test for overall effect: Z = 4					00001	,, - ,	U / U		
		0.0000	•,						
Total (95% CI)			1 281			1281	100.0%	-6.48 [-8.60, -4.35]	◆
Heterogeneity: Tau ² = 18.38	; Chi ² =	88.51.	df = 33	(P < 0.	00001); ² = 6	3%		
Test for overall effect: Z = 5				,					-50 -25 0 25 50
Test for subaroup difference	•			P = 0.4	1). l² =	0%			Favours [Post-ablation] Favours [Pre-ablation]

Fig 3. A forest plot of comparison: changes in maximum left atrial volume (LAVmax) pre-ablation and post-ablation.

doi:10.1371/journal.pone.0129274.g003

except for LAD with AF recurrence (WMD, 2.25 mm; 95%CI, from 0.29 mm to 4.21 mm, P = 0.02, <u>S1 Fig</u>). The LAEF (WMD, -4.60%; 95%CI, from -7.91% to -1.29%, P = 0.006, <u>S4 Fig</u>) and LAAEF (WMD, -8.60%; 95%CI, from -13.46% to -3.74%, P = 0.0005, <u>S5 Fig</u>) were decreased significantly in patients with recurrence AF after CA during follow-up, however, there were insignificant changes between those with no recurrence AF.

Heterogeneity Analysis

After performing a heterogeneity test, the existence of heterogeneity among those studies should not be ignored. To demonstrate the origin of the heterogeneity, a meta-regression analysis and sensitivity analysis were performed. Heterogeneity was significant in spite which individual study was excluded. As previously illustrated, a subgroup analysis was performed; each

	Post	-ablati	ion	Pre-	ablati	on		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% Cl	IV. Random, 95% Cl
3.1.1 LAVmin Studies With	h Paroxy	/smal .	AF						
Erdei PAF Nonrecur 2012	32	11	15	30	12	15	3.4%	2.00 [-6.24, 10.24]	
Erdei PAF Recur 2012	44	20	21	38	19	21	2.1%	6.00 [-5.80, 17.80]	
Hof PAF 2013	57.9	18.9	90	62.8	20	90	4.8%	-4.90 [-10.59, 0.79]	
Lemola PAF 2005	78	27	27	87	39	27	1.1%	-9.00 [-26.89, 8.89]	
Montserrat PAF 2011	28	11	77	30	12	77	6.1%	-2.00 [-5.64, 1.64]	
Nori PAF 2009	16.3	5.9	16	19.7	5.7	16	5.9%	-3.40 [-7.42, 0.62]	
Subtotal (95% CI)			246			246	23.4%	-2.42 [-4.70, -0.15]	\blacksquare
Heterogeneity: Tau ² = 0.00;	Chi ² = 4	.59, df	= 5 (P	= 0.47)	; ² = 0	%			
Test for overall effect: Z = 2	.09 (P =	0.04)							
3.1.2 LAVmin Studies With	h Persis	tent A	F						
Hof PeAF 2013	73.8	27.1	37	80.2	31.2	37	1.8%	-6.40 [-19.72, 6.92]	
Machino PeAF Nonrecur	23	12	62	40	19	62	4.8%	-17.00 [-22.59, -11.41]	— —
Machino PeAF Recur	49	20	45	47	16	45	3.8%	2.00 [-5.48, 9.48]	
Montserrat PeAF 2011	39	16	77	46	18	77	5.0%	-7.00 [-12.38, -1.62]	
Nori PeAF 2009	24	8.8	13	31.7	9.3	13	4.0%	-7.70 [-14.66, -0.74]	
Subtotal (95% CI)			234			234	19.4%	-7.54 [-14.05, -1.03]	
Heterogeneity: Tau ² = 40.09	9; Chi² =	16.88,	df = 4 ((P = 0.0	02); I²	= 76%			
Test for overall effect: Z = 2	.27 (P =	0.02)							
3.1.3 LAVmin Studies With	h Pooled	i Data							
Choi 2008	35.1	12.9	33	43.8		33	3.7%	-8.70 [-16.31, -1.09]	
Delgado Nonrecur 2008	24	8	21	26	13	21	4.3%	-2.00 [-8.53, 4.53]	
Delgado Recur 2008	30	15	13	32	12	13	2.5%	-2.00 [-12.44, 8.44]	
Jahnke Nonrecur 2011	50.4	18.4	31		23.7	31	2.5%	-17.80 [-28.36, -7.24]	
Jahnke Recur 2011	71.3	23.8	10	80.2	24.9	10	0.8%	-8.90 [-30.25, 12.45]	
Marsan Nonrecur 2008	10	4	38	13	5	38	7.0%	-3.00 [-5.04, -0.96]	
Marsan Recur 2008	18	6	19	16	7	19	5.8%	2.00 [-2.15, 6.15]	
Perea Nonrecur 2008		12.1	38	58.6	16.1	38	4.3%	-6.40 [-12.80, 0.00]	
Perea Recur 2008	75.8	24.3	17	78.4	22.2	17	1.4%	-2.60 [-18.25, 13.05]	
Rodrigues 2009	34	15	28	30	15	28	3.6%	4.00 [-3.86, 11.86]	
Tops 2011	12	5	93	19	6	93	7.2%	-7.00 [-8.59, -5.41]	+
Tops Nonrecur 2006	31	7	39	37	9	39	6.1%	-6.00 [-9.58, -2.42]	
Tops Recur 2006	47	7	18	43	7	18	5.5%	4.00 [-0.57, 8.57]	—
Verma 2006	66.8	13.9	26	78.6	23.8	26	2.5%	-11.80 [-22.39, -1.21]	
Subtotal (95% CI)			424			424	57.3%	-3.82 [-6.49, -1.15]	
Heterogeneity: Tau ² = 13.89	•			(P < 0	.00001); ² = 7	4%		
Test for overall effect: Z = 2	.80 (P =	0.005)							
T-4-1 (05% OI)			00.4			004	400.007	4471004 0401	
Total (95% CI)			904	(m			100.0%	-4.17 [-6.21, -2.13]	, ▼ ,
Heterogeneity: Tau ² = 14.32				· (P < 0	.00001); ² = 7	1%		-20 -10 0 10 20
Test for overall effect: Z = 4	•		,	-					Favours [Post-ablation] Favours [Pre-ablation]
Test for subaroup difference	es: Chi ² =	= 2.35.	df = 2 (P = 0.3	51), ² =	: 14.7%	•		



PLOS

outcome was analyzed based on the AF type (PAF or PeAF). A random effects model was used to combine the effect size because significant heterogeneity was shown as an all-total consequence.

Subsequently, a sensitivity analysis that was on the basis of image modalities, the LAVmax (WMD, -9.31 mL; 95%CI, from -12.45 mL to -6.16 mL, P < 0.00001, <u>S7 Fig</u>) and LAVmin (WMD, -6.07 mL; 95%CI, from -8.49 mL to -3.65 mL, P < 0.00001, <u>S8 Fig</u>) remained significant decreased at post-ablation which detected by cardiac magnetic resonance imaging (CMR) and/or Computed Tomography (CT). However, the LAD (WMD, -0.77 mm; 95%CI, from -2.87 mm to 1.33 mm, P = 0.47, <u>S6 Fig</u>), LAEF (WMD, -0.28%; 95%CI, from -3.91% to 3.35%, P = 0.88, <u>S9 Fig</u>) and LAAEF (WMD, -2.47%; 95%CI, from -6.30% to 1.36%, P = 0.21, <u>S10 Fig</u>) were not significant change during follow-up after catheter ablation treatment. And then, we found that the LAVmax (WMD, -7.08 mL; 95%CI, from -12.52 mL to -1.64 mL, P = 0.01, <u>S7 Fig</u>), LAVmin (WMD, -4.07 mL; 95%CI, from -7.29 mL to -0.84 mL, P = 0.01, <u>S8 Fig</u>) and LAEF (WMD, -5.72%; 95%CI, from -11.02% to -0.42%, P = 0.03, <u>S9 Fig</u>) were significant decrease in PAF; the LAV (LAVmax: WMD, -8.90 mL; 95%CI, from -15.28 mL to -2.53 mL,

	Post	-ablati	on	Pre-	ablati	on		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% Cl
4.1.1 LAEF Studies With I	Paroxysr	nal AF					_		
Erdei PAF Nonrecur 2012	55	9	15	55	8	15	4.2%	0.00 [-6.09, 6.09]	_
Erdei PAF Recur 2012	47	11	21	48	11	21	4.0%	-1.00 [-7.65, 5.65]	
Lemola PAF 2005	21	8	27	32	13	27	4.3%	-11.00 [-16.76, -5.24]	
Masuda PAF 2012	44.9	10.6	92	47.4	11.8	92	5.3%	-2.50 [-5.74, 0.74]	
Montserrat PAF 2011	40	13	77	44	16	77	4.8%	-4.00 [-8.60, 0.60]	
Nori PAF 2009	42.7	9.4	16	47.3	10.1	16	3.9%	-4.60 [-11.36, 2.16]	
Subtotal (95% Cl)			248			248	26.4%	-3.80 [-6.65, -0.95]	\bullet
Heterogeneity: Tau ² = 5.33	; Chi² = 8	.83, df	= 5 (P	= 0.12)	; ² = 4	3%			
Test for overall effect: Z = 2	2.61 (P =	0.009)							
4.1.2 LAEF Studies With I	Persister	nt AF							
Machino PeAF Nonrecur	36	14	62	24	17	62	4.4%	12.00 [6.52, 17.48]	
Machino PeAF Recur	17	14	45	21	16	45	4.1%	-4.00 [-10.21, 2.21]	—•+
Masuda PeAF 2012	39.1	11.5	23	32.7	11.4	23	4.0%	6.40 [-0.22, 13.02]	
Montserrat PeAF 2011	31	17	77	28	16	77	4.5%	3.00 [-2.21, 8.21]	+
Nori PeAF 2009	34.8	10.2	13	24.1	11.8	13	3.3%	10.70 [2.22, 19.18]	
Subtotal (95% CI)			220			220	20.3%	5.47 [-0.25, 11.20]	
Heterogeneity: Tau ² = 32.0	2; Chi ² =	16.76,	df = 4	(P = 0.0	102); l²	= 76%			
Test for overall effect: Z = 1	1.87 (P =	0.06)							
4.1.3 LAEF Studies With I									
Choi 2008	30.9	10	33	31.8	12.8	33	4.4%	-0.90 [-6.44, 4.64]	
Delgado Nonrecur 2008	48	18	21	49	19	21	2.5%	-1.00 [-12.19, 10.19]	
Delgado Recur 2008	43	13	13	49	14	13	2.7%	-6.00 [-16.39, 4.39]	
Hof 2013	41.2	9.6	127	43.8	9.3	127	5.6%	-2.60 [-4.92, -0.28]	-•]
Jahnke Nonrecur 2011	40.7	13.2	31	31.4	17.3	31	3.6%	9.30 [1.64, 16.96]	
Jahnke Recur 2011	34.9	13.9	10	31.8	15.2	10	2.1%	3.10 [-9.67, 15.87]	
Marsan Nonrecur 2008	58	10	38	52	10	38	4.8%	6.00 [1.50, 10.50]	
Marsan Recur 2008	42	11	19	47	13	19	3.6%	-5.00 [-12.66, 2.66]	
Perea Nonrecur 2008	38.1	9.8	38		11.5	38	4.7%	-2.10 [-6.90, 2.70]	
Perea Recur 2008	26.9	10.2	17	37.4	10.1	17		-10.50 [-17.32, -3.68]	
Rodrigues 2009	43	8	28	47	8	28	4.9%	-4.00 [-8.19, 0.19]	
Tops 2011	46	11	93	41	14	93	5.2%	5.00 [1.38, 8.62]	
Verma 2006	22.1	5.4	26	16.7	5.8	26	5.4%	5.40 [2.35, 8.45]	
Subtotal (95% CI)			494			494	53.2%	-0.01 [-2.99, 2.97]	—
Heterogeneity: Tau ² = 20.0	-		df = 12	2 (P < 0.	.00001); ² = 7	7%		
Test for overall effect: Z = ().01 (P =	0.99)							
Total (95% Cl)			962			962	100.0%	0.07 [-2.22, 2.36]	•
Heterogeneity: Tau ² = 23.1	0; Chi² =	105.37	7, df = 2	23 (P < 6	0.0000	1); l² =	78%		
Test for overall effect: Z = 0				•					-20 -10 0 10 20 Favours [Post-ablation] Favours [Pre-ablation]
Test for subaroup difference	es: Chi² =	= 9.01.	df = 2	(P = 0.0	1). ² =	77.8%	•		

Fig 5. A forest plot of comparison: changes in left atrial ejective fraction (LAEF) pre-ablation and post-ablation.

doi:10.1371/journal.pone.0129274.g005

P = 0.006, <u>S7 Fig</u>; LAVmin: WMD, -7.42 mL; 95%CI, from -13.59 mL to -1.25 mL, P = 0.02, <u>S8</u> Fig) were decreased significantly in PeAF, however, the LAEF (WMD, 8.03%; 95%CI, from 2.81% to 13.24%, P = 0.003, <u>S9 Fig</u>) was increased significantly in PeAF.

According to a sensitivity analysis that was based on a follow-up of >6 months, there were significant decreases in only LAV after catheter ablation therapy, including LAVmax (WMD, -6.07 mL; 95%CI, from -8.76 mL to -3.38 mL, P < 0.00001, S12 Fig) and LAVmin (WMD, -3.91 mL; 95%CI, from -6.62 mL to -1.20 mL, P = 0.005; S13 Fig). However, the LAD, LAEF, and LAAEF did not significantly change during follow-up after ablation treatment (WMD, -0.81 mm; 95%CI, from -1.68 mm to 0.06 mm, P = 0.07; WMD, 0.05%; 95%CI, from -2.67% to 2.77%, P = 0.97; WMD, 2.89%; 95%CI, from -2.42% to 8.20%, P = 0.29; respectively, S11, S14 and S15 Figs).

A sensitivity analysis was performed based on a follow-up of >12 months. After ablation therapy, the LAVmax (WMD, -7.83 mL; 95%CI, from -11.65 mL to -4.01 mL, P < 0.0001, S17 Fig) and LAVmin (WMD, -5.90 mL; 95%CI, from -9.77 mL to -2.03 mL, P = 0.003, S18 Fig) were significantly decreased; however, the LAD and LAEF did not significantly change (WMD, -0.36 mm; 95%CI, from -1.53 mm to 0.81 mm, P = 0.55; WMD, 0.80%; 95%CI, from -3.03% to 4.63%, P = 0.68; respectively, S16 and S19 Figs).




Fig 6. A forest plot of comparison: changes in left atrial active ejective fraction (LAAEF) pre-ablation and post-ablation.

doi:10.1371/journal.pone.0129274.g006

ONE

PLOS

Subsequently, a meta-regression analysis was performed to determine the heterogeneity origin. However, we did not find any factors that contributed to the heterogeneity.

Publication Bias Analysis

Egger's test and Begg's funnel plot were used to evaluate publication bias. There were no significant risks of publication bias according to an analysis using Stata 12.0 (the *P* value for each test was >0.05; <u>Table 3</u>). The funnel plot was generally symmetrical, and it indicated that the publication bias for the studies was controlled.

Discussion

In the present review, we found that the LA volumes and LAD were significantly decreased after CA therapy during follow-up imaging. Nonetheless, we did not find any significant changes in LA function (included LAEF and LAAEF) after ablation treatment during follow-up imaging. Furthermore, there were significant decreases in the LA volumes and LAEF with

	Post	-ablati	ion	Pre-	ablati	on		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% Cl	IV. Random, 95% Cl
Choi 2008	44.8	16.7	33	60.7	22.7	33	13.2%	-15.90 [-25.52, -6.28]	— — —
Dagres PAF 2009	53	12	289	59	23	289	16.6%	-6.00 [-8.99, -3.01]	•
Delgado Nonrecur 2008	30	26	21	31	27	21	9.5%	-1.00 [-17.03, 15.03]	6
Delgado Recur 2008	42	16	9	22	36	8	5.2%	20.00 [-7.05, 47.05]	
Machino PeAF Nonrecur	63	19	16	54	12	16	12.4%	9.00 [-2.01, 20.01]	+
Muller 2008	59	16.1	91	59.7	20.4	91	15.6%	-0.70 [-6.04, 4.64]	
Rodrigues 2009	58	19	28	55	15	28	13.6%	3.00 [-5.97, 11.97]	
Verma 2006	61.9	17.3	41	42.8	20.9	41	14.0%	19.10 [10.80, 27.40]	
Total (95% CI)			528			527	100.0%	1.94 [-5.46, 9.33]	•
Heterogeneity: Tau ² = 83.5	57; Chi² =	= 47.44	1, df = 7	(P < 0.	.00001); ² = 8	5%		
Test for overall effect: Z =	-								-50 -25 0 25 50 Favours [Post-ablation] Favours [Pre-ablation]

Fig 7. A forest plot of comparison: changes in A wave velocity pre-ablation and post-ablation.

doi:10.1371/journal.pone.0129274.g007



Post-	ablati	on	Pre-	ablatio	on		Mean Difference	Mean Difference
Mean	SD	Total	Mean	SD	Total	Weight	IV. Random. 95% C	I IV. Random. 95% Cl
7.6	1.6	33	9.7	1.9	33	22.6%	-2.10 [-2.95, -1.25]	— e —
10.8	3.1	15	10.7	2.7	15	15.8%	0.10 [-1.98, 2.18]	P
10.2	2.7	21	9.8	2.1	21	19.3%	0.40 [-1.06, 1.86]	
9.8	3.4	91	8.9	2.9	91	22.3%	0.90 [-0.02, 1.82]	- -
8.1	2.8	28	7.9	2.3	28	20.0%	0.20 [-1.14, 1.54]	
		188			188	100.0%	-0.14 [-1.51, 1.23]	
Chi ² = 25	5.30, d	if = 4 (F	- < 0.00	01); I²	= 84%			
.20 (P = ().84)							-4 -2 0 2 4 Favours [Post-ablation] Favours [Pre-ablation]
	Mean 7.6 10.8 10.2 9.8 8.1 Chi ² = 25	Mean SD 7.6 1.6 10.8 3.1 10.2 2.7 9.8 3.4 8.1 2.8	7.6 1.6 33 10.8 3.1 15 10.2 2.7 21 9.8 3.4 91 8.1 2.8 28 188 Chi ² = 25.30, df = 4 (f	Mean SD Total Mean 7.6 1.6 33 9.7 10.8 3.1 15 10.7 10.2 2.7 21 9.8 9.8 3.4 91 8.9 8.1 2.8 28 7.9 188 Chi² = 25.30, df = 4 (P < 0.000	Mean SD Total Mean SD 7.6 1.6 33 9.7 1.9 10.8 3.1 15 10.7 2.7 10.2 2.7 21 9.8 2.1 9.8 3.4 91 8.9 2.9 8.1 2.8 28 7.9 2.3 188 Chi² = 25.30, df = 4 (P < 0.0001); I²	Mean SD Total Mean SD Total 7.6 1.6 33 9.7 1.9 33 10.8 3.1 15 10.7 2.7 15 10.2 2.7 21 9.8 2.1 21 9.8 3.4 91 8.9 2.9 91 8.1 2.8 2.8 7.9 2.3 28 188 188 Chi² = 25.30, df = 4 (P < 0.0001); l² = 84%	Mean SD Total Mean SD Total Weight 7.6 1.6 33 9.7 1.9 33 22.6% 10.8 3.1 15 10.7 2.7 15 15.8% 10.2 2.7 21 9.8 2.1 21 19.3% 9.8 3.4 91 8.9 2.9 91 22.3% 8.1 2.8 28 7.9 2.3 28 20.0% IB8 188 100.0% Chi² = 25.30, df = 4 (P < 0.0001); l² = 84%	Mean SD Total Mean SD Total Weight IV. Random. 95% C 7.6 1.6 33 9.7 1.9 33 22.6% -2.10 [-2.95, -1.25] 10.8 3.1 15 10.7 2.7 15 15.8% 0.10 [-1.98, 2.18] 10.2 2.7 21 9.8 2.1 21 19.3% 0.40 [-1.06, 1.86] 9.8 3.4 91 8.9 2.9 91 22.3% 0.90 [-0.02, 1.82] 8.1 2.8 2.8 7.9 2.3 2.8 20.0% 0.20 [-1.14, 1.54] 188 100.0% -0.14 [-1.51, 1.23] Chi² = 25.30, df = 4 (P < 0.0001); l² = 84%



paroxysmal AF after CA treatment. However, we did not find any significant changes in outcomes, as previously detailed, for persistent AF after ablation therapy, except for LA volumes.

CA is a therapeutic method for terminating the underlying electrophysiological mechanism of AF. The substrate and trigger foci are isolated by freezing (cryoablation) or radiofrequency energy and then terminate the electrical conduction from the pulmonary vein (PV) to LA. Currently, CA is approved by the Food and Drug Administration (FDA) for managing paroxysmal AF. Although this practical strategy is also used for managing non-paroxysmal AF, unfortunately, it is not yet approved by the FDA [2, 35]. The resumption of a sinus rhythm with CA is a perfect consequence, but the amount of LA scarring produced by CA could influence LA structural and functional remodeling, especially with repeated ablation. Structural remodeling includes increasing LA size and a change in LA strain. Several studies [10, 18, 19] reported that the enlargement could be reversed after successful ablation therapy that is defined as the maintenance of a sinus rhythm during follow-up [34]. Thus, LA reverse remodeling may become a robust sign of successful CA for patients with AF. Further studies should be conducted to evaluate the effects on LA function for patients with AF after a repeat ablation treatment.

There was a significant decrease in LAEF after CA treatment in studies with paroxysmal AF; however, we did not find similar outcomes in studies with persistent AF. Rodrigues et al. [17] reported a degradation in LAEF after CA for patients with paroxysmal AF at a follow-up duration of about 8 months after performing transthoracic echocardiography (TTE). Hof et al. [11] found a similar outcome using three-dimensional computed tomography (CT). However, Erdei et al. [10] and Machino-Ohtsuka et al. [13] described that the LAEF was preserved and even increased in patients without an AF recurrence at a follow-up of >12 months; however, it had decreased in AF recurrence patients after TTE and CMR. Why did this phenomenon occur in these studies? Several reasons for this variance should be considered, including the

Primary Outcome	Begg's Test (P value)	Egger's Test (P value)
LAD	0.921	0.636
LAVmax	0.767	0.832
LAVmin	0.726	0.670
LAEF	0.785	0.948
LAAEF	1.000	0.605
A Wave	0.536	0.205
A' Wave	0.086	0.117

Table 3. Assessment of publication bias with Stata 12.0 for each primary outcome.

Abbreviations as previously detailed.

doi:10.1371/journal.pone.0129274.t003

follow-up duration after CA therapy; the chronicity of AF; the different clinical outcomes; and the different degrees of tissue damage related to the different ablation strategies, tools, or both.

More consideration should be given to the follow-up duration regarding studying LA function and size. Studies with a long follow-up (not less than 12 months) [12, 13, 19] have illustrated significant increases in LAEF after ablation treatment in AF patients; however, insignificant changes in LAEF with paroxysmal AF in 3 months follow-up [14, 16]. Further, a sensitivity analysis based on the follow-up duration was not persuasive because of a lack of detailed individual patient data. McGann et al. [36] reported that the quantification and detection of left atrial wall scarring would be applicable 3 months after CA in patients with AF. As we known, there is a phenomenon of atrial "stunning" during in 1 month follow-up after catheter ablation therapy, and either the LA size or the LA function is unstable change. After the "blanking period" (about 3 months), which the rate of recurrence AF is highest [37], the quantification and detection of LA size and function is more credible and accurate. Therefore, it is important that a longer follow-up duration should be performed for evaluating LA function. Moreover, because the LA function was assessed using only the sinus rhythm (SR), it is difficult to evaluate LA function in permanent AF patients.

In addition, the imaging technique is another important factor. Many different methods were performed in the studies, including TTE [9, 10, 13-15, 17-20, 22, 24, 26-32], CMR [11, 12, 16, 25, 33], and CT [14, 21, 23, 27]. As an established method in cardiac imaging modalities, TTE can identify the size of each chamber, as well as the ejection fraction of the LA and left ventricle (LV). However, a limitation occurs if patients are obese and have serious obstructive pulmonary disease with poor acoustic windows [38]. Multidetector Computed Tomography (MDCT) has a prominent temporal and spatial resolution for measuring LA volumes. CMR can concurrently discover pre-ablation fibrosis and post-ablation scar tissue and measure PV anatomy in patients who undergo CA therapy [39]. As we known, different analytical methods or image tools would obtain different results. Compare to TTE, using CMR and CT have a prominent temporal and spatial resolution for measuring LA volumes and EF, the results of CMR or CT should be more accurate than that of TEE. Due to this important issue, we performed subgroup analysis based on the variant methods of image. Subsequently, after excluding studies using TTE, only 9 studies (enrolled 635 patients) [11, 12, 14, 16, 21, 23, 25, 27, 33] were included in the subgroup analysis on the basis of detecting by CMR and/or CT. The LA volumes significantly decreased, LAEF/LAAEF insignificant changed. The explanations for this phenomenon as follow. First, CMR and CT/MDCT are more accuracy and improve reproducibility in measurement of LA volumes and functions compare to TTE. Second, the numbers of included studies were decreased, and then it may influence the pooled data. Therefore, compared with MDCT and CMR, TTE may underestimate the true LA size and function.

Nonetheless, there is no gold standard for measuring LA function. In the present review, the LAEF was used to define LA function in 15 studies [10–17, 19, 23, 27–29, 31, 33], and only 6 studies used LAAEF to define LA function [11, 15, 16, 24, 29, 31]. Furthermore, A wave velocity [9, 13, 17, 27–29, 32] and A' wave velocity [10, 17, 28, 32] were used to define LA contractile function. The A wave velocity involves the peak velocities of the late transmitral flow, as measured by pulsed-wave DE, reflecting LA systolic function from hemodynamics, but it is not sensitive because it can be affected by the LV diastolic function and preload. However, compared with the A wave velocity, the A' wave velocity, as detailed previously, is an easy and effective means to assess LA systolic function from tissue motion because it is correlated with changes in the LA systolic area and volume [8]. Therefore, further studies should be conducted to assess this method for evaluating LA function.

Beyond these, the treatment strategy and energy of catheter ablation are another factor. In this meta-analysis, the majority of included studies were used RFCA, only one study [10]

performed cryoablation. As we known, different treatment strategies, such as SPVI and PVAI, lead to different outcomes, and diverse ablation temperature and power resulted in different damages for atrium. The included studies used RFCA were set at a similar value of the ablation temperature and power, and therefore, the results have consistency and comparability. After excluding the study performed cryoablation, there were similar pooled data compare to previous detailed. Due to there was no more available data, further studies should be focused on evaluating the effects on LA function and size for patients with AF after cryoablation treatment.

Heterogeneity is an important issue for explaining the outcomes of this review, and significant heterogeneity was found in this meta-analysis. Subsequently, sensitivity analyses were performed, and heterogeneity was significant in spite which individual study was excluded. We did not find any contributing factor for the heterogeneity with a meta-regression. The quality of the included articles may be the origin of heterogeneity.

Moreover, our review had some limitations. First, we did not consider any randomized control trial in this meta-analysis; the sample sizes of the included studies were small, and most were single center and either a prospective or retrospective study that may have added potential biases to such studies. Second, it is difficult to draw decisive conclusions regarding LA functional change after ablation therapy, because of inconsistencies regarding individual patient data, the imaging method, and the follow-up duration. Third, although publication bias was not significant after performing an Egger's test and a Begg's funnel plot, the influence of bias in this article could not be thoroughly excluded, as only studies published in English were included. Forth, we have tried addressing an issue but indirectly regarding the effectiveness of CA for AF by looking at LA size and function, however, it is a pooled data and it has its own set of issues which precludes us from providing any more clarity. Moreover, another limitation is the lack of a gold standard to measure LA function among these involved studies. Currently, MDCT and CMR are considered relatively accurate methods for measuring LA function and size. Finally, although several studies reported that the LA volumes and sizes are predictors of AF recurrence after CA therapy [40-42], our review did not perform an analysis based on AF recurrence in different types of AF. Therefore, we do not know the relationship between AF recurrence and LA function/size among different types of AF.

In conclusion, With CA, LA volumes and LAD were decreased significantly in patients with AF; LAEF was not significant changes in patients with PeAF but decreased in those with PAF.

Supporting Information

S1 Checklist. The PRISMA Checklist. (DOC)

S1 Fig. A forest plot of comparison: changes in left atrial diameter (LAD) pre-ablation and post-ablation on the basis of atrial fibrillation recurrence. (TIF)

S2 Fig. A forest plot of comparison: changes in maximum left atrial volume (LAVmax) preablation and post-ablation on the basis of atrial fibrillation recurrence. (TIF)

S3 Fig. A forest plot of comparison: changes in minimum left atrial volume (LAVmin) preablation and post-ablation on the basis of atrial fibrillation recurrence. (TIF) S4 Fig. A forest plot of comparison: changes in left atrial ejective fraction (LAEF) pre-ablation and post-ablation on the basis of atrial fibrillation recurrence. (TIF)

S5 Fig. A forest plot of comparison: changes in left atrial active ejective fraction (LAAEF) pre-ablation and post-ablation on the basis of atrial fibrillation recurrence. (TIF)

S6 Fig. A forest plot of comparison: changes in left atrial diameter (LAD) pre-ablation and post-ablation detected by cardiac magnetic resonance imaging and/or computed tomography.

(TIF)

S7 Fig. A forest plot of comparison: changes in maximum left atrial volume (LAVmax) preablation and post-ablation detected by cardiac magnetic resonance imaging and/or computed tomography.

(TIF)

S8 Fig. A forest plot of comparison: changes in minimum left atrial volume (LAVmin) preablation and post-ablation detected by cardiac magnetic resonance imaging and/or computed tomography.

(TIF)

S9 Fig. A forest plot of comparison: changes in left atrial ejective fraction (LAEF) pre-ablation and post-ablation detected by cardiac magnetic resonance imaging and/or computed tomography.

(TIF)

S10 Fig. A forest plot of comparison: changes in left atrial active ejective fraction (LAAEF) pre-ablation and post-ablation detected by cardiac magnetic resonance imaging and/or computed tomography.

(TIF)

S11 Fig. A forest plot of comparison: changes in left atrial diameter (LAD) pre-ablation and post-ablation during follow-up more than 6 months. (TIF)

S12 Fig. A forest plot of comparison: changes in maximum left atrial volume (LAVmax) pre-ablation and post-ablation during follow-up more than 6 months. (TIF)

S13 Fig. A forest plot of comparison: changes in minimum left atrial volume (LAVmin) pre-ablation and post-ablation during follow-up more than 6 months. (TIF)

S14 Fig. A forest plot of comparison: changes in left atrial ejective fraction (LAEF) preablation and post-ablation during follow-up more than 6 months. (TIF)

S15 Fig. A forest plot of comparison: changes in left atrial active ejective fraction (LAAEF) pre-ablation and post-ablation during follow-up more than 6 months. (TIF)

S16 Fig. A forest plot of comparison: changes in left atrial diameter (LAD) pre-ablation and post-ablation during follow-up more than 12 months. (TIF)

S17 Fig. A forest plot of comparison: changes in maximum left atrial volume (LAVmax) pre-ablation and post-ablation during follow-up more than 12 months. (TIF)

S18 Fig. A forest plot of comparison: changes in minimum left atrial volume (LAVmin) pre-ablation and post-ablation during follow-up more than 12 months. (TIF)

S19 Fig. A forest plot of comparison: changes in left atrial ejective fraction (LAEF) preablation and post-ablation during follow-up more than 12 months. (TIF)

Acknowledgments

We would like to thank everyone who contributed to this research. This study was not supported by any fund.

Author Contributions

Conceived and designed the experiments: LS BX DL JW LG JJ. Performed the experiments: BX DL JW. Analyzed the data: BX DL JJ. Contributed reagents/materials/analysis tools: BX JW. Wrote the paper: BX LG.

References

- Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, et al. ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2012; 14(8):1094–103. Epub 2012/05/26. doi: <u>10.1093/europace/ eus153</u> PMID: <u>22628450</u>.
- Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European heart journal. 2010; 31(19):2369–429. Epub 2010/08/31. doi: <u>10.1093/</u> <u>eurheartij/ehq278</u> PMID: <u>20802247</u>.
- Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. Journal of the American College of Cardiology. 2007; 49(9):986–92. Epub 2007/03/06. doi: <u>10.1016/j.jacc.2006.10.062</u> PMID: <u>17336723</u>.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke; a journal of cerebral circulation. 1991; 22(8):983–8. Epub 1991/08/01. PMID: 1866765.
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114(7):e257–354. Epub 2006/08/16. doi: 10.1161/circulationaha.106.177292 PMID: 16908781.

- Jeevanantham V, Ntim W, Navaneethan SD, Shah S, Johnson AC, Hall B, et al. Meta-analysis of the effect of radiofrequency catheter ablation on left atrial size, volumes and function in patients with atrial fibrillation. The American journal of cardiology. 2010; 105(9):1317–26. doi: <u>10.1016/j.amjcard.2009.12</u>. <u>046</u> PMID: <u>20403486</u>.
- Hesse B, Schuele SU, Thamilasaran M, Thomas J, Rodriguez L. A rapid method to quantify left atrial contractile function: Doppler tissue imaging of the mitral annulus during atrial systole. European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2004; 5(1):86–92. Epub 2004/04/29. PMID: <u>15113019</u>.
- Dagres N, Hindricks G, Kottkamp H, Varounis C, Bode K, Arya A, et al. Effect of atrial fibrillation ablation on left atrial contractile function in patients with paroxysmal atrial fibrillation and a relatively well preserved atrial function. Acta Cardiologica. 2009; 64(2):167–9. doi: <u>10.2143/ac.64.2.2035339</u> PMID: <u>19476107</u>
- Erdei T, Denes M, Kardos A, Mihalcz A, Foldesi C, Temesvari A, et al. Could successful cryoballoon ablation of paroxysmal atrial fibrillation prevent progressive left atrial remodeling? Cardiovascular ultrasound. 2012; 10:11. doi: <u>10.1186/1476-7120-10-11</u> PMID: <u>22429696</u>; PubMed Central PMCID: PMC3364153.
- Hof IE, Vonken EJ, Velthuis BK, Wittkampf FH, van der Heijden JF, Neven KG, et al. Impact of pulmonary vein antrum isolation on left atrial size and function in patients with atrial fibrillation. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing. 2013. doi: <u>10</u>. 1007/s10840-013-9860-0 PMID: 24317918.
- Jahnke C, Fischer J, Gerds-Li JH, Gebker R, Manka R, Fleck E, et al. Serial monitoring of reverse leftatrial remodeling after pulmonary vein isolation in patients with atrial fibrillation: a magnetic resonance imaging study. International journal of cardiology. 2011; 153(1):42–6. doi: <u>10.1016/j.ijcard.2010.08.034</u> PMID: <u>20828842</u>.
- Machino-Ohtsuka T, Seo Y, Ishizu T, Yanaka S, Nakajima H, Atsumi A, et al. Significant Improvement of Left Atrial and Left Atrial Appendage Function After Catheter Ablation for Persistent Atrial Fibrillation. Circulation Journal. 2013; 77(7):1695–704. doi: <u>10.1253/circj.CJ-12-1518</u> PMID: <u>23535197</u>
- Masuda M, Inoue K, Iwakura K, Okamura A, Koyama Y, Kimura R, et al. The impact of atrial fibrillation ablation on left atrial function: association with baseline left atrial function. Pacing and clinical electrophysiology: PACE. 2012; 35(3):327–34. doi: 10.1111/j.1540-8159.2011.03284.x PMID: 22150125.
- Montserrat S, Sitges M, Calvo N, Silva E, Tamborero D, Vidal B, et al. Effect of repeated radiofrequency catheter ablation on left atrial function for the treatment of atrial fibrillation. The American journal of cardiology. 2011; 108(12):1741–6. doi: 10.1016/j.amjcard.2011.07.041 PMID: 21906703.
- Nori D, Raff G, Gupta V, Gentry R, Boura J, Haines DE. Cardiac magnetic resonance imaging assessment of regional and global left atrial function before and after catheter ablation for atrial fibrillation. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing. 2009; 26(2):109–17. doi: 10.1007/s10840-009-9409-4 PMID: 19629666.
- Rodrigues AC, Scannavacca MI, Caldas MA, Hotta VT, Pisani C, Sosa EA, et al. Left atrial function after ablation for paroxysmal atrial fibrillation. The American journal of cardiology. 2009; 103(3):395–8. doi: 10.1016/j.amjcard.2008.09.094 PMID: 19166696.
- Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, et al. Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart rhythm: the official journal of the Heart Rhythm Society. 2012; 9(4):473–80. doi: <u>10.</u> <u>1016/j.hrthm.2011.11.013</u> PMID: 22079885.
- Tops LF, Delgado V, Bertini M, Marsan NA, Den Uijl DW, Trines SA, et al. Left atrial strain predicts reverse remodeling after catheter ablation for atrial fibrillation. Journal of the American College of Cardiology. 2011; 57(3):324–31. doi: <u>10.1016/j.jacc.2010.05.063</u> PMID: <u>21232671</u>.
- Yoshida N, Okamoto M, Hirao H, Suenari K, Nanba K, Kinoshita H, et al. Efficacy of pulmonary vein isolation on left atrial function in paroxysmal and persistent atrial fibrillation and the dependency on its baseline function. Echocardiography. 2013; 30(7):744–50. doi: <u>10.1111/echo.12143</u> PMID: <u>23461708</u>.
- **21.** Lemola K, Sneider M, Desjardins B, Case I, Chugh A, Hall B, et al. Effects of left atrial ablation of atrial fibrillation on size of the left atrium and pulmonary veins. Heart rhythm: the official journal of the Heart Rhythm Society. 2004; 1(5):576–81. doi: 10.1016/j.hrthm.2004.07.020 PMID: 15851222.
- Beukema WP, Elvan A, Sie HT, Misier AR, Wellens HJ. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. Circulation. 2005; 112 (14):2089–95. doi: 10.1161/CIRCULATIONAHA.104.484766 PMID: 16203925.
- Lemola K, Desjardins B, Sneider M, Case I, Chugh A, Good E, et al. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart rhythm: the official journal of the Heart Rhythm Society. 2005; 2(9):923–8. doi: 10.1016/j.hrthm.2005.06.026 PMID: 16171744.

- Reant P, Lafitte S, Jais P, Serri K, Weerasooriya R, Hocini M, et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005; 112(19):2896–903. doi: 10.1161/CIRCULATIONAHA.104.523928 PMID: 16260634.
- Tsao HM, Wu MH, Huang BH, Lee SH, Lee KT, Tai CT, et al. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insight from long-term follow-up of threedimensional magnetic resonance imaging. Journal of cardiovascular electrophysiology. 2005; 16(1):7– 12. doi: <u>10.1046/j.1540-8167.2005.04407.x</u> PMID: <u>15673379</u>.
- Tops LF, Bax JJ, Zeppenfeld K, Jongbloed MR, van der Wall EE, Schalij MJ. Effect of radiofrequency catheter ablation for atrial fibrillation on left atrial cavity size. The American journal of cardiology. 2006; 97(8):1220–2. doi: <u>10.1016/j.amjcard.2005.11.043</u> PMID: <u>16616029</u>.
- Verma A, Kilicaslan F, Adams JR, Hao S, Beheiry S, Minor S, et al. Extensive ablation during pulmonary vein antrum isolation has no adverse impact on left atrial function: an echocardiography and cine computed tomography analysis. Journal of cardiovascular electrophysiology. 2006; 17(7):741–6. doi: 10.1111/j.1540-8167.2006.00488.x PMID: 16836670.
- Choi JI, Park SM, Park JS, Hong SJ, Pak HN, Lim do S, et al. Changes in left atrial structure and function after catheter ablation and electrical cardioversion for atrial fibrillation. Circulation journal: official journal of the Japanese Circulation Society. 2008; 72(12):2051–7. PMID: <u>18948668</u>.
- Delgado V, Vidal B, Sitges M, Tamborero D, Mont L, Berruezo A, et al. Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation. The American journal of cardiology. 2008; 101(9):1285–90. doi: 10.1016/j.amjcard.2007.12.028 PMID: 18435959.
- 30. Liu Z, Ling Z, Su L, Wu J, Lan X, Chen Y, et al. The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing. 2008; 23(3):167–73. doi: 10.1007/s10840-008-9301-7 PMID: 18810622.
- Marsan NA, Tops LF, Holman ER, Van de Veire NR, Zeppenfeld K, Boersma E, et al. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. The American journal of cardiology. 2008; 102(7):847–53. doi: <u>10.1016/j.amjcard.</u> <u>2008.05.048</u> PMID: <u>18805109</u>.
- 32. Muller H, Noble S, Keller PF, Sigaud P, Gentil P, Lerch R, et al. Biatrial anatomical reverse remodelling after radiofrequency catheter ablation for atrial fibrillation: evidence from real-time three-dimensional echocardiography. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2008; 10(9):1073–8. doi: 10.1093/europace/eun187 PMID: 18628258.
- Perea RJ, Tamborero D, Mont L, De Caralt TM, Ortiz JT, Berruezo A, et al. Left atrial contractility is preserved after successful circumferential pulmonary vein ablation in patients with atrial fibrillation. Journal of cardiovascular electrophysiology. 2008; 19(4):374–9. doi: 10.1111/j.1540-8167.2007.01086.x PMID: 18266672.
- 34. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart rhythm: the official journal of the Heart Rhythm Society. 2007; 4(6):816–61. Epub 2007/06/09. doi: 10.1016/j.hrthm.2007.04.005 PMID: 17556213.
- Wazni O, Wilkoff B, Saliba W. Catheter ablation for atrial fibrillation. The New England journal of medicine. 2011; 365(24):2296–304. Epub 2011/12/16. doi: <u>10.1056/NEJMct1109977</u> PMID: <u>22168644</u>.
- McGann CJ, Kholmovski EG, Oakes RS, Blauer JJ, Daccarett M, Segerson N, et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. Journal of the American College of Cardiology. 2008; 52(15):1263–71. Epub 2008/10/18. doi: 10.1016/j.jacc.2008.05.062 PMID: 18926331.
- Uchiyama T, Miyazaki S, Taniguchi H, Komatsu Y, Kusa S, Nakamura H, et al. Six-Year Follow-up of Catheter Ablation in Paroxysmal Atrial Fibrillation. Circulation Journal. 2013; 77(11):2722–7. doi: <u>10.</u> <u>1253/circj.CJ-13-0468</u> PMID: <u>23924888</u>
- Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Journal of the American College of Cardiology. 2003; 42(5):954–70. Epub 2003/09/06. PMID: 12957449.

- 39. Tops LF, van der Wall EE, Schalij MJ, Bax JJ. Multi-modality imaging to assess left atrial size, anatomy and function. Heart (British Cardiac Society). 2007; 93(11):1461–70. Epub 2007/10/16. doi: <u>10.1136/hrt.2007.116467</u> PMID: <u>17934005</u>; PubMed Central PMCID: PMCPMC2016891.
- 40. Sohns C, Sohns JM, Vollmann D, Luthje L, Bergau L, Dorenkamp M, et al. Left atrial volumetry from routine diagnostic work up prior to pulmonary vein ablation is a good predictor of freedom from atrial fibrillation. European heart journal cardiovascular Imaging. 2013; 14(7):684–91. Epub 2013/02/26. doi: 10.1093/ehjci/jet017 PMID: 23435593.
- Miyazaki S, Kuwahara T, Kobori A, Takahashi Y, Takei A, Sato A, et al. Preprocedural predictors of atrial fibrillation recurrence following pulmonary vein antrum isolation in patients with paroxysmal atrial fibrillation: long-term follow-up results. Journal of cardiovascular electrophysiology. 2011; 22(6):621–5. Epub 2011/01/18. doi: 10.1111/j.1540-8167.2010.01984.x PMID: 21235666.
- 42. Shin SH, Park MY, Oh WJ, Hong SJ, Pak HN, Song WH, et al. Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2008; 21(6):697–702. Epub 2008/01/12. doi: 10.1016/j.echo.2007.10.022 PMID: 18187293.